Latest On 111, Inc (YI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-26 19:21 EST | News | 111, Inc.: Moving Toward Profitability In The Telehealth Sector | N/A |  |
| 2023-03-24 05:20 EST | News | 111, Inc. (YI) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-23 13:13 EST | News | 111 Non-GAAP EPADS of -$0.08, revenue of $601.4M | N/A | |
| 2022-12-15 21:53 EST | News | 111, Inc.: Privatization With An Interesting Twist | N/A | |
| 2022-12-01 23:35 EST | News | 111, Inc. (YI) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-12-01 23:35 EST | News | 111, Inc. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-12-01 05:12 EST | News | 111 Non-GAAP EPADS of -$0.10, revenue of $470.8M | N/A | |
| 2022-09-09 16:33 EST | News | 111 stock rises 15% on co-founders' offer to take Chinese online drug retailer private | N/A | |
| 2022-08-25 23:32 EST | News | 111, Inc. (YI) Q2 2022 Earnings Call Transcript | N/A | |
| 2022-08-25 07:12 EST | News | 111 Non-GAAP EPS of -$0.14, revenue of $453.4M | N/A | |
| 2022-08-25 07:12 EST | News | 111, Inc. 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-07-27 01:14 EST | News | 111, Inc.'s Inexorable Drive Towards Profitability | N/A | |
| 2022-06-17 06:46 EST | News | 111, Inc.'s (YI) CEO Junling Liu on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-06-16 13:09 EST | News | 111 Non-GAAP EPADS of -$0.14, revenue of $470.5M | N/A | |
| 2022-03-18 08:43 EST | News | 111 GAAP EPADS of -$0.22, revenue of $543.1M | N/A | |
| 2022-03-18 08:43 EST | News | 111, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-18 08:43 EST | News | 111, Inc. (YI) CEO Junling Liu On Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-04 16:56 EST | News | 111, Beilin Pharmaceutical team up to explore digital marketing of Chinese patent drugs | N/A | |
| 2021-11-20 02:07 EST | News | 111, Inc. 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-20 02:07 EST | News | 111, Inc. (YI) CEO Junling Liu on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-19 05:15 EST | News | 111 reports Q3 results | N/A | |
| 2021-10-27 10:57 EST | News | Warning: YI is at high risk of performing badly | N/A | |
| 2021-10-25 10:38 EST | News | 111 trades in green on strategic partnership with Chugai Pharma China | N/A | |
| 2021-10-08 20:54 EST | News | YI is at high risk of performing badly | N/A | |
| 2021-09-22 17:38 EST | News | Solid Earnings, Modest Buyback Fail To Boost Drug Seller 111, Inc. | N/A | |
| 2021-09-07 06:39 EST | News | 111 approves $10M share repurchase program | N/A | |
| 2021-08-27 22:03 EST | News | 111, Inc. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-27 22:03 EST | News | 111, Inc. (YI) CEO Junling Liu on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-18 23:25 EST | News | 111, Inc.: Undervalued After Recent Unjustified Share Price Collapse; 50% Upside | N/A | |
| 2021-08-04 00:46 EST | News | 111 announces cooperation agreement with Suzhou Zelgen Biopharmaceuticals | N/A | |
| 2021-04-17 01:07 EST | News | IOVA, LSCC, WIT and GSX among premarket gainers | N/A | |
| 2021-03-26 02:45 EST | News | 111 inks strategic cooperation agreement with Jianming Pharmaceutical | N/A | |
| 2021-03-23 17:09 EST | News | 111 Inc.: Bullish On Chinese Online Pharmacy Distributor And Retailer | N/A | |
| 2021-03-19 08:43 EST | News | 111, Inc. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-03-19 08:43 EST | News | 111, Inc. (YI) CEO Junling Liu on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-19 00:38 EST | Analyst Rating | The Analyst Target Price has decreased from $16 to $15.98. | Sell | |
| 2021-03-18 11:40 EST | News | 111 reports Q4 results | N/A | |
| 2021-03-18 11:40 EST | News | HEXO, CSIQ, LAZR and SIG among premarket gainers | N/A | |
| 2021-03-18 11:15 EST | Analyst Rating | The Analyst Target Price has decreased from $16.01 to $16. | Sell | |
| 2021-03-17 23:32 EST | Analyst Rating | The Analyst Target Price has increased from $15.97 to $16.01. | Neutral | |
| 2021-03-17 16:13 EST | News | 111 inks strategic partnership with BeiGene | N/A | |
| 2021-03-17 15:25 EST | Analyst Rating | The Analyst Target Price has decreased from $15.99 to $15.97. | Sell | |
| 2021-03-16 23:55 EST | Analyst Rating | The Analyst Target Price has decreased from $16.03 to $15.99. | Sell | |
| 2021-03-12 22:34 EST | Analyst Rating | The Analyst Target Price has increased from $15.9 to $16.03. | Neutral | |
| 2021-03-10 22:25 EST | Analyst Rating | The Analyst Target Price has increased from $15.83 to $15.9. | Neutral | |
| 2021-03-09 22:31 EST | Analyst Rating | The Analyst Target Price has decreased from $15.9 to $15.83. | Sell | |
| 2021-03-08 22:14 EST | Analyst Rating | The Analyst Target Price has decreased from $15.99 to $15.9. | Neutral | |
| 2021-03-05 22:27 EST | Analyst Rating | The Analyst Target Price has increased from $15.95 to $15.99. | Buy | |
| 2021-03-05 09:59 EST | Analyst Rating | The Analyst Target Price has decreased from $15.96 to $15.95. | Neutral | |
| 2021-03-03 22:23 EST | Analyst Rating | The Analyst Target Price has increased from $15.95 to $15.96. | Neutral | |
About 111, Inc (YI):
111, Inc., through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2019, it operated 12 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Shanghai, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has a strategic partnership with Bayer Healthcare Co. Ltd. to develop a digitalized content portal that would provide online pharmacist training and interactive patient education content and services. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
General
- Name 111, Inc
- Symbol YI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryPharmaceutical Retailers
- Full Time Employees 1,932
- Fiscal Year EndDecember
- IPO Date2018-09-12
- Gic SectorConsumer Staples
- Gic GroupFood & Staples Retailing
- Gic IndustryFood & Staples Retailing
- Gic SubIndustryDrug Retail
- Web URLhttp://www.111.com.cn
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 1.4
- Price/Book (Most Recent Quarter) 20.04
- Enterprise Value Revenue 0.2
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -7%
- Return on Assets -14%
- Return on Equity -53%
- Earnings Per Share -$1.27
- Revenue Per Share $0
- Gross Profit 36.19 million
- Quarterly Earnings Growth 112.8%
View More
Highlights
- Market Capitalization 1.35 billion
- Analyst Target Price $15.98
- Book Value Per Share $2.49
View More
Share Statistics
- Shares Outstanding 82.36 million
- Shares Float 24.02 million
- % Held by Insiders <1%
- % Held by Institutions 7.15%
- Shares Short 1.24 million
- Shares Short Prior Month 244618
- Short Ratio 0.62
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 1.01
- 52 Week High $30.99
- 52 Week Low $5.29
- 50 Day Moving Average 17.5
- 200 Day Moving Average 9.53
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
111, Inc (YI) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
111, Inc (YI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-19 | $N/A | -$0.19 | ||
| 2020-06-30 | 2020-09-30 | $1.62 billion | -$0.19 | ||
| 2020-03-31 | 2020-06-30 | $1.58 billion | -$0.16 | ||
| 2019-12-31 | 2020-03-31 | $1.35 billion | -$0.21 | ||
| 2019-09-30 | 2019-12-31 | $1.11 billion | -$0.28 | ||
| 2019-06-30 | 2019-09-30 | $838.16 million | -$0.21 | ||
| 2019-03-31 | 2019-06-30 | $655.6 million | -$0.18 | ||
| 2018-12-31 | 2019-03-31 | $248996.23 | -$0.22 | ||
| 2018-09-30 | 2018-12-31 | $72.45 million | -$0.22 | ||
| 2018-06-30 | 2018-09-30 | $60.1 million | -$0.41 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $52.58 million | -$0.36 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $44.72 million | -$0.19 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $38.56 million | -$0.27 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $35.73 million | -$0.26 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $28.47 million | -$0.25 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $125.86 million | -$0.25 | $0.00 |
111, Inc (YI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
111, Inc (YI) Chart:
111, Inc (YI) News:
Below you will find a list of latest news for 111, Inc (YI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
111, Inc (YI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.4 | PUT | 0 | 3 | 537.45 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 913.5 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 1103.56 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.05 | CALL | 0 | 37 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 1.15 | PUT | 0 | 8 | 231.38 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0 | PUT | 0 | 0 | 308.33 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | PUT | 0 | 0 | 351.22 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.05 | CALL | 0 | 102 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 1.4 | PUT | 0 | 1 | 189.51 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 3.8 | PUT | 0 | 1 | 159.11 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 191.75 | TRUE | 0 | 0 |
Latest YI Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 54 | $1.84 |
| Jun 13, 2022 7:59 PM EST | 38 | $1.84 |
| Jun 13, 2022 7:59 PM EST | 11 | $1.85 |
| Jun 13, 2022 7:59 PM EST | 17 | $1.84 |
| Jun 13, 2022 7:59 PM EST | 354 | $1.83 |
111, Inc (YI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000095010320009965/0000950103-20-009965-index.htm |
| 2018-06-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1738906/000000000018018286/0000000000-18-018286-index.htm |
| 2018-07-09 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1738906/000000000018020874/0000000000-18-020874-index.htm |
| 2018-09-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1738906/000000000018027500/0000000000-18-027500-index.htm |
| 2018-06-26 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1738906/000091205718000283/0000912057-18-000283-index.htm |
| 2018-07-27 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1738906/000091205718000318/0000912057-18-000318-index.htm |
| 2020-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000095010320009965/0000950103-20-009965-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000095010320016136/0000950103-20-016136-index.htm |
| 2020-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000095010320021641/0000950103-20-021641-index.htm |
| 2018-08-15 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1738906/000104746918005629/0001047469-18-005629-index.htm |
| 2018-08-29 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1738906/000104746918005870/0001047469-18-005870-index.htm |
| 2018-09-07 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1738906/000104746918006029/0001047469-18-006029-index.htm |
| 2018-09-07 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1738906/000104746918006034/0001047469-18-006034-index.htm |
| 2018-09-13 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1738906/000104746918006196/0001047469-18-006196-index.htm |
| 2018-08-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1738906/000110465918052234/0001104659-18-052234-index.htm |
| 2018-08-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1738906/000110465918054120/0001104659-18-054120-index.htm |
| 2018-08-29 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1738906/000110465918054121/0001104659-18-054121-index.htm |
| 2018-09-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1738906/000110465918055721/0001104659-18-055721-index.htm |
| 2018-09-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1738906/000110465918055739/0001104659-18-055739-index.htm |
| 2018-09-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1738906/000110465918055740/0001104659-18-055740-index.htm |
| 2018-11-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465918067129/0001104659-18-067129-index.htm |
| 2019-01-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919002386/0001104659-19-002386-index.htm |
| 2019-01-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000110465919002419/0001104659-19-002419-index.htm |
| 2019-01-22 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1738906/000110465919002594/0001104659-19-002594-index.htm |
| 2019-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000110465919003506/0001104659-19-003506-index.htm |
| 2019-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000110465919003508/0001104659-19-003508-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000110465919008280/0001104659-19-008280-index.htm |
| 2019-02-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919010879/0001104659-19-010879-index.htm |
| 2019-03-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919013518/0001104659-19-013518-index.htm |
| 2019-04-10 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919020555/0001104659-19-020555-index.htm |
| 2019-05-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919029987/0001104659-19-029987-index.htm |
| 2019-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919046435/0001104659-19-046435-index.htm |
| 2019-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465919064492/0001104659-19-064492-index.htm |
| 2020-01-29 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000110465920007814/0001104659-20-007814-index.htm |
| 2020-02-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000110465920024156/0001104659-20-024156-index.htm |
| 2020-03-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000110465920032745/0001104659-20-032745-index.htm |
| 2020-04-16 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1738906/000110465920047214/0001104659-20-047214-index.htm |
| 2019-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1738906/000114420419006212/0001144204-19-006212-index.htm |
| 2018-09-04 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1738906/000135445718000336/0001354457-18-000336-index.htm |
| 2018-05-17 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1738906/000141057818000252/0001410578-18-000252-index.htm |
| 2018-06-26 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1738906/000141057818000297/0001410578-18-000297-index.htm |
| 2018-07-27 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1738906/000141057818000348/0001410578-18-000348-index.htm |
| 2019-05-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1738906/000141057819000252/0001410578-19-000252-index.htm |
| 2018-09-12 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1738906/999999999518002345/9999999995-18-002345-index.htm |